Hyloris Pharmaceuticals SA (EBR:HYL)
Belgium · Delayed Price · Currency is EUR 6.70
+0.36 (5.68%)
Aug 22, 2025, 5:39 PM CET
Hyloris Pharmaceuticals Revenue
In the year 2024, Hyloris Pharmaceuticals had annual revenue of 9.76M EUR with 159.64% growth. Hyloris Pharmaceuticals had revenue of 5.12M in the half year ending December 31, 2024, with 278.14% growth.
Revenue
9.76M
Revenue Growth
+159.64%
P/S Ratio
19.22
Revenue / Employee
199.18K
Employees
49
Market Cap
187.60M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 9.76M | 6.00M | 159.64% |
| Dec 31, 2023 | 3.76M | 1.37M | 57.48% |
| Dec 31, 2022 | 2.39M | -709.00K | -22.90% |
| Dec 31, 2021 | 3.10M | 2.92M | 1,669.14% |
| Dec 31, 2020 | 175.00K | 84.00K | 92.31% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UCB SA | 6.85B |
| argenx SE | 2.66B |
| Financière de Tubize | 13.26K |
| Fagron NV | 918.75M |
| Ion Beam Applications | 498.16M |
| Onward Medical | 1.74M |
| Nyxoah | 4.93M |
| Sequana Medical NV | 105.50K |